Appelhans Dannielle insider trades
Appelhans Dannielle has filed 13 Form 4s with the SEC that we hold, for GBIO (Director), RUBY (CEO and President) and Halozyme Therapeutics, INC. (HALO) (Director). Across all of them we count 3 purchases worth $32.3K and 3 sales worth $6.9K reported on Form 4. None of these purchases or sales is dated in the last 12 months. The largest single trade was a purchase of 12,000 shares of GBIO worth $18.0K, dated 2023-12-04. The first filing on our record is dated 2021-09-01 and the latest 2026-09-02.
GBIO
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-12-04 | P, purchase reported on Form 4 | 12,000 | $18.0K | 2023-12-06 |
| 2023-12-08 | P, purchase reported on Form 4 | 637 | $1.2K | 2023-12-11 |
| 2023-12-08 | P, purchase reported on Form 4 | 7,363 | $13.2K | 2023-12-11 |
RUBY
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-08-10 | S, sale reported on Form 4 | 5,737 | $4.6K | 2022-08-12 |
| 2023-02-01 | S, sale reported on Form 4 | 3,878 | $970 | 2023-02-01 |
| 2023-02-24 | S, sale reported on Form 4 | 10,385 | $1.4K | 2023-02-27 |
Halozyme Therapeutics, INC. (HALO)
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Counted from the Form 4 filings this reporting owner (SEC CIK 1874962) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms